Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study
Background: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies...
Main Authors: | , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/10/15/3214 |
id |
doaj-997ea0974b1e43c584a1a18cd994db4f |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Antonio Muro Moncef Belhassen-García Juan Luís Muñoz Bellido Helena Lorenzo Juanes Belén Vicente Josué Pendones José Adserias Gonzalo Sánchez Hernández Miguel Rodríguez Rosa José Luis Vicente Villardón Javier Burguillo Javier López Andaluz Jose Angel Martín Oterino Francisco Javier García Criado Fausto Barbero Ana Isabel Morales Purificación Galindo Villardón Rogelio González Sarmiento on behalf of the DIANCUSAL Team |
spellingShingle |
Antonio Muro Moncef Belhassen-García Juan Luís Muñoz Bellido Helena Lorenzo Juanes Belén Vicente Josué Pendones José Adserias Gonzalo Sánchez Hernández Miguel Rodríguez Rosa José Luis Vicente Villardón Javier Burguillo Javier López Andaluz Jose Angel Martín Oterino Francisco Javier García Criado Fausto Barbero Ana Isabel Morales Purificación Galindo Villardón Rogelio González Sarmiento on behalf of the DIANCUSAL Team Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study Journal of Clinical Medicine SARS-CoV-2 COVID-19 antibodies seroprevalence screening university |
author_facet |
Antonio Muro Moncef Belhassen-García Juan Luís Muñoz Bellido Helena Lorenzo Juanes Belén Vicente Josué Pendones José Adserias Gonzalo Sánchez Hernández Miguel Rodríguez Rosa José Luis Vicente Villardón Javier Burguillo Javier López Andaluz Jose Angel Martín Oterino Francisco Javier García Criado Fausto Barbero Ana Isabel Morales Purificación Galindo Villardón Rogelio González Sarmiento on behalf of the DIANCUSAL Team |
author_sort |
Antonio Muro |
title |
Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study |
title_short |
Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study |
title_full |
Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study |
title_fullStr |
Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study |
title_full_unstemmed |
Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL Study |
title_sort |
seroprevalence of sars-cov-2 antibodies and factors associated with seropositivity at the university of salamanca: the diancusal study |
publisher |
MDPI AG |
series |
Journal of Clinical Medicine |
issn |
2077-0383 |
publishDate |
2021-07-01 |
description |
Background: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. Objective: The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. Methodology: The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July–October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. Principal findings: A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (<i>p</i> = 0.006). Based on the questionnaire, loss of smell and fever were the symptoms most strongly associated with seropositivity, and 22.6% of seropositive participants were asymptomatic. Social distancing was the most effective hygiene measure (<i>p</i> = 0.0007). There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (<i>p</i> = 0.0000), but not between students who lived in private homes and those who lived in dormitories. IgG antibodies decreased over time in the participants with confirmed self-reported COVID-19 diagnoses. Conclusions: The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures. |
topic |
SARS-CoV-2 COVID-19 antibodies seroprevalence screening university |
url |
https://www.mdpi.com/2077-0383/10/15/3214 |
work_keys_str_mv |
AT antoniomuro seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT moncefbelhassengarcia seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT juanluismunozbellido seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT helenalorenzojuanes seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT belenvicente seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT josuependones seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT joseadserias seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT gonzalosanchezhernandez seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT miguelrodriguezrosa seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT joseluisvicentevillardon seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT javierburguillo seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT javierlopezandaluz seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT joseangelmartinoterino seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT franciscojaviergarciacriado seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT faustobarbero seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT anaisabelmorales seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT purificaciongalindovillardon seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT rogeliogonzalezsarmiento seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy AT onbehalfofthediancusalteam seroprevalenceofsarscov2antibodiesandfactorsassociatedwithseropositivityattheuniversityofsalamancathediancusalstudy |
_version_ |
1721218178347958272 |
spelling |
doaj-997ea0974b1e43c584a1a18cd994db4f2021-08-06T15:26:28ZengMDPI AGJournal of Clinical Medicine2077-03832021-07-01103214321410.3390/jcm10153214Seroprevalence of SARS-CoV-2 Antibodies and Factors Associated with Seropositivity at the University of Salamanca: The DIANCUSAL StudyAntonio Muro0Moncef Belhassen-García1Juan Luís Muñoz Bellido2Helena Lorenzo Juanes3Belén Vicente4Josué Pendones5José Adserias6Gonzalo Sánchez Hernández7Miguel Rodríguez Rosa8José Luis Vicente Villardón9Javier Burguillo10Javier López Andaluz11Jose Angel Martín Oterino12Francisco Javier García Criado13Fausto Barbero14Ana Isabel Morales15Purificación Galindo Villardón16Rogelio González Sarmiento17on behalf of the DIANCUSAL TeamInfectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainInfectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainInfectious and Tropical Diseases Group (e-INTRO), Institute of Biomedical Research of Salamanca-Research Center for Tropical Diseases at the University of Salamanca (IBSAL-CIETUS), Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainIT Department, University of Salamanca Foundation (FGUSAL), University of Salamanca, 37008 Salamanca, SpainData Processing Center (CPD), University of Salamanca, 37008 Salamanca, SpainDepartment of Statistics, University of Salamanca, 37008 Salamanca, SpainDepartment of Statistics, University of Salamanca, 37008 Salamanca, SpainDepartment of Chemistry-Physics, Faculty of Pharmacy, University of Salamanca, 37008 Salamanca, SpainDepartment of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainDepartment of Nursing and Phisiotherapy, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainDepartment of Statistics, University of Salamanca, 37008 Salamanca, SpainInstitute of Biomedical Research of Salamanca (IBSAL), University of Salamanca, University Hospital of Salamanca, 37007 Salamanca, SpainBackground: Systematic screening for antibodies against SARS-CoV-2 is a crucial tool for surveillance of the COVID-19 pandemic. The University of Salamanca (USAL) in Spain designed a project called “DIANCUSAL” (Diagnosis of New Coronavirus, COVID-19, in University of Salamanca) to measure antibodies against SARS-CoV-2 among its ~34,000 students and academic staff, as the influence of the university community in the spread of the SARS-CoV-2 pandemic in the city of Salamanca and neighboring towns hosting USAL campuses could be substantial. Objective: The aim of this study was to estimate the prevalence of SARS-CoV-2 antibodies among USAL students, professors and staff and to evaluate the demographic, academic, clinical and lifestyle and behavioral factors related to seropositivity. Methodology: The DIANCUSAL study is an ongoing university population-based cross-sectional study, with the work described herein conducted from July–October 2020. All USAL students, professors and staff were invited to complete an anonymized questionnaire. Seroprevalence of anti-SARS-CoV-2 antibodies was detected and quantified by using chemiluminescent assays for IgG and IgM. Principal findings: A total of 8197 (24.71%) participants were included. The mean age was 31.4 (14.5 SD) years, and 66.0% of the participants were female. The seroprevalence was 8.25% overall and was highest for students from the education campus (12.5%) and professors from the biomedical campus (12.6%), with significant differences among faculties (<i>p</i> = 0.006). Based on the questionnaire, loss of smell and fever were the symptoms most strongly associated with seropositivity, and 22.6% of seropositive participants were asymptomatic. Social distancing was the most effective hygiene measure (<i>p</i> = 0.0007). There were significant differences in seroprevalence between participants with and without household exposure to SARS-CoV-2 (<i>p</i> = 0.0000), but not between students who lived in private homes and those who lived in dormitories. IgG antibodies decreased over time in the participants with confirmed self-reported COVID-19 diagnoses. Conclusions: The analysis revealed an overall 8.25% seroprevalence at the end of October 2020, with a higher seroprevalence in students than in staff. Thus, there is no need for tailored measures for the USAL community as the official average seroprevalence in the area was similar (7.8% at 22 June and 12.4 at 15 November of 2020). Instead, USAL members should comply with public health measures.https://www.mdpi.com/2077-0383/10/15/3214SARS-CoV-2COVID-19antibodiesseroprevalencescreeninguniversity |